Scientific & Technological Advances in Cancer Research
Integrated Approaches to Effective Detection, Prognosis and Treatment of Cancer
This event took place: February 11-13, 2004 - Hyatt Regency Reston - Reston, VA

Exciting new advances in technologies and breakthroughs in cancer biology will yield quantum leaps towards a better understanding of the molecular basis of cancer, and thus the ability to control and eliminate it. To take full advantage of these opportunities, academia, government and industry researchers need to hone in their efforts collectively to achieve an integrated approach for the effective detection, diagnosis, prognosis and treatment of cancer.

For the 2nd year running, IBC and the Center for Cancer Research have come together to co-organize this scientific meeting, Advances in Cancer Research, to accelerate the exchange of information among scientists, provide a forum for researchers to showcase their research and innovations as well as open the door towards greater collaborations.

Scientists from academia and the private sector came to this conference to:

• Hear updates on the science, including developments in prevention trials, new biomarkers, target identification, mouse models and clinical updates of targeted therapeutics
• Evaluate technologies and their applications in cancer detection, clinical decisions and treatment response
• Network with top scientists in cancer research, including pharmaceutical and biotech leaders, academia and government experts
• Actively participate in facilitated roundtables and point-counterpoint debates
• Submit a poster of your latest research results, and get direct feedback from the outstanding scientists present at the event Advances in Cancer Research is strategically scheduled back-to-back with IBC's Biomarkers, to facilitate more efficient networking among attendees of both events. Given the synergy in the topics discussed, IBC is offering a special savings up to $1000 for attendees who sign up for the 5-day/2-conference package.

Organizing Committee

Daniel Chan, Ph.D. DABCC, FACB., Professor of Pathology, Oncology, Radiology & Urology, Director of Biomarker Discovery Center, School of Medicine, Johns Hopkins Medical Institutions

Nancy Colburn, Ph.D., Chair, Cancer Prevention Faculty, National Cancer Institute

David Goldstein, Ph.D., Chief, Office of Science and Technology Partners, Center for Cancer Research, National Cancer Institute

Garret Hampton, Ph.D., Head, Department of Cancer and Cell Biology, Genomics Institute of Novartis Research Foundation

Moncef Jendoubi, Ph.D., DES, Founder, President & CEO, Milagen Inc .

Yan Li, Ph.D., Senior Scientist & Project Leader, Centocor Inc. (Johnson & Johnson)

Cheryl Marks, Ph.D., Associate Director, Division of Cancer Biology, MMHCC Program Director, National Cancer Institute

Emanuel Petricoin, Ph.D., Co-Director, FDA & NCI Clinical Proteomics Program, CBER, Food and Drug Administration

Daniel Pinkel, Ph.D., Cancer Genetics, University of California San Francisco

Shoshana Segal, Ph.D., Assistant Director for Technology Development, Center for Cancer Research, National Cancer Institute

Patricia Steeg, Ph.D., Chair, Molecular Targets Faculty, National Cancer Institute